Clinical Significance and Prognostic Factors of Simultaneous Heart Valve Surgery and Coronary Artery Bypass Grafting in Treating Patients with Valvular Heart Disease Complicated by Coronary Heart Disease

2021 ◽  
Vol 7 (5) ◽  
pp. 1203-1213
Author(s):  
Shi Qiu ◽  
Jinhui Sun
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Coronary Artery Bypass ◽  
Artery Bypass ◽  
Valve Surgery ◽  
Bypass Grafting ◽  
Heart Valve Surgery ◽  
Artery Bypass Grafting

This study was designed to evaluate the clinical significance of simultaneous heart valve surgery and coronary artery bypass grafting for patients with valvular heart disease complicated by coronary heart disease and its influence on their prognosis. A total of 121 patients with valvular heart disease complicated by coronary heart disease who were surgically treated in our hospital from January 2013 to March 2017 were selected. The observation group (OG) (64 patients) underwent simultaneous valvular heart surgery and coronary artery bypass grafting. The control group (CG) (57 patients) underwent non-synchronous heart valve surgery and coronary artery bypass grafting. The operation, hospitalization, occurrence of adverse events and changes of cardiac function indexes of patients from the two groups were compared, and the factors affecting their prognosis were confirmed in multivariate analysis. The ventilator application time, postoperative ICU monitoring time, postoperative general ward time and total incidence of adverse events in the OG were lower than those in the CG (P<0.05). After treatment, the cardiothoracic ratio, left ventricular end-diastolic volume and BNP content in the two groups were markedly higher than before treatment, and the increase in the OG was more obvious (P<0.05); the left ventricular ejection fraction in both groups was markedly lower than that before treatment (P<0.05), and the decrease in the OG was more obvious (P<0.05). Multivariate analysis showed that hypertension, treatment methods, course of disease and age were independent risk factors affecting the prognosis of patients with valvular heart disease complicated by coronary heart disease. Simultaneous heart valve surgery and coronary artery bypass grafting can reduce the occurrence of adverse events and improve cardiac function indexes, which is worthy of clinical application. Hypertension, treatment methods, course of disease and age are independent risk factors affecting the prognosis of those patients.

scholarly journals Neuropsychological outcomes of coronary artery bypass grafting

2004 ◽  
Vol 9 (3) ◽  
Author(s):  
Nafisa Cassimjee ◽  
Caroline L Couzens ◽  
Frans J Smith ◽  
Claire Wagner
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Coronary Artery Bypass ◽  
Full Text ◽  
Artery Bypass ◽  
Bypass Grafting ◽  
Artery Bypass Grafting ◽  
Neuropsychological Outcomes

People with coronary heart disease have recourse to a palliative intervention such as Coronary Artery Bypass Grafting (CABG). Opsomming Persone met ‘n koronêre hartsiekte is soms genoodsaak om ‘n hartomleiding (CABG), wat ‘n tydelike intervensie ter verligting is, te ondergaan. *Please note: This is a reduced version of the abstract. Please refer to PDF for full text.

Use of 99mTc-HMPAO in Evaluating the Results of Cerebral Hypoperfusion Prevention in the Patients with Coronary Heart Disease after Coronary Artery Bypass Grafting

2015 ◽  
Vol 1084 ◽  
pp. 506-510
Author(s):  
Nataliya Yu. Efimova ◽  
Vladimir I. Chernov ◽  
Irina Yu. Efimova ◽  
Shamil D. Akhmedov ◽  
Yuri B. Lishmanov
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Coronary Artery Bypass ◽  
Artery Bypass ◽  
Bypass Grafting ◽  
Artery Bypass Grafting ◽  
Cerebral Complications ◽  
Preventive Medication

The purpose of this study is to research the use of the radiopharmaceutical99mTc-HMPAO in the evaluation of drug prevention of cerebral complications in patients with coronary heart disease after coronary artery bypass grafting (CABG) performed with cardiopulmonary bypass (CPB). The study included 30 patients, in whom surgical revascularization was performed with CPB. 11 patients in this group were prescribed instenon. All the patients underwent brain tomoscintigraphy with99mTc-HMPAO and neuropsychological testing before CABG and 10-15 days after it. The results showed that99mTc-HMPAO is useful radiopharmaceutical for evaluation of cerebral complications in patients after CABG. Thus, coronary artery bypass grafting using CPB can be complicated by the deterioration of cerebral perfusion and cognitive dysfunction, while preventive medication with instenon can prevent or significantly reduce the violations of cerebral hemodynamics and neuropsychological status of the patients.

scholarly journals Interleukin-8 in Hyperlipidemia and Coronary Heart Disease in Thai Patients Taking Statin Cholesterol-Lowering Medication While Undergoing Coronary Artery Bypass Grafting Treatment

Scientifica ◽  
2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Wilanee Dechkhajorn ◽  
Yaowapa Maneerat ◽  
Kriengchai Prasongsukarn ◽  
Panan Kanchanaphum ◽  
Ratchanok Kumsiri
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Mrna Expression ◽  
Coronary Artery Bypass ◽  
Artery Bypass ◽  
Bypass Grafting ◽  
Cholesterol Lowering ◽  
Artery Bypass Grafting

The role of interleukin-8 (IL-8), a pivotal chemokine in atherogenesis and coronary heart disease (CHD) development, is diverse and remains unclear. This cross-sectional study investigates the association of the IL-8 expression in hyperlipidemia (H) and CHD patients who have been treated with statin cholesterol-lowering drugs while undergoing coronary artery bypass grafting treatment. Fifty-five Thai volunteers including 13 normal (N), 24 H, and 18 CHD patients were enrolled for the investigation. All the CHD patients had been treated continuously with statin cholesterol-lowering medications since the disease was diagnosed and were undergoing coronary bypass grafting approximately one month later. Therefore, the CHD group was representative of a pathogenesis improvement in CHD. The IL8 mRNA expression was determined by real-time quantitative PCR in the peripheral blood mononuclear cells from heparinized blood. The plasma IL-8 levels were assessed by enzyme-linked immunosorbent assay. The result shows that the IL8 mRNA expression in the H group tended to increase; however, in the CHD group, there was a significant decrease (p=0.0111) compared to the N group. The IL8 mRNA expression and the plasma levels in the CHD group were significantly lower than those in the H group (p<0.05). A significant negative correlation between the IL8 mRNA (r = −0.499) or plasma IL-8 (r = −0.3875) expression and CHD progression was observed (p<0.05). In conclusion, the transcriptomic and the phenotypic IL-8 expression decreased significantly in the Thai CHD patients who had continuously received statin-group medications compared to the H and N group participants. Therefore, IL-8 should serve as a feasible marker and could be used to evaluate the therapeutic effects of statins and illustrate the pathology of CHD treatment.

Sign in / Sign up

Export Citation Format

Share Document